Results 221 to 230 of about 61,821 (357)
Radionuclide Selection Influences Imaging Outcomes in Immuno-PET with a Brain-Penetrating Anti-Amyloid-β Antibody. [PDF]
Lopes van den Broek S +5 more
europepmc +1 more source
Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival [PDF]
Jonas Kloepper +26 more
openalex +1 more source
ABSTRACT Introduction Acquired haemophilia A (AHA) is a rare autoimmune disorder where the development of autoantibodies to factor (F)VIII neutralise its function, leading to bleeding. Emicizumab has been approved for treating AHA in Japan. Aim This post‐marketing study was performed to primarily examine the use and safety of emicizumab, and indirectly
Midori Shima +8 more
wiley +1 more source
Trial Watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics. [PDF]
Xue E +4 more
europepmc +1 more source
Seventh Åland Island Meeting on von Willebrand Disease
ABSTRACT Introduction The seventh Åland Island Meeting on von Willebrand Disease (VWD) was held on the Åland archipelago in Finland, from 26 to 28 September 2024. Aim The meeting brought together experts in the field of VWD from around the world to share the latest advances and knowledge in VWD.
Riitta Lassila +17 more
wiley +1 more source
Abstracts for the 2026 Immunotherapy and Precision Oncology Forum: April 11, 2026, Cincinnati, OH, USA. [PDF]
europepmc +1 more source
Erratum: A KRAS<sup>G12V</sup>-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [PDF]
Huynh N +4 more
europepmc +1 more source
ABSTRACT Introduction Performance‐based measures are essential for detecting early musculoskeletal functional limitations in patients with haemophilia (PwH). The Weight‐Bearing Lunge Test (WBLT) assesses ankle dorsiflexion mobility, but its psychometric properties in PwH remain unclear.
Firat Tan +3 more
wiley +1 more source

